The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Open accessAbstract
BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Flagged first, then by citations
Research works printed but not linked: 3
- 10.2307/2281868 · DOI · Paper page
- Berger RL, 1996, Am Stat, 50, 314
- Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610
Cited by
Sorted by citations
Items 301–400 of 1,000
LoPiccolo, J., Schollenberger, M. D., Dakhil, S., Rosner, S., Ali, O., Sharfman, W. H., Silk, A. W., Bhatia, S., & Lipson, E. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0661-6 · Cited by 51
Self-citationRicci, C., Righi, A., Ambrosi, F., Gibertoni, D., Maletta, F., Uccella, S., Sessa, F., Asioli, S., Pellilli, M., Maragliano, R., et al. (2019) · Endocrine Pathology · doi:10.1007/s12022-019-09601-5 · Cited by 51
Aguilera, J. V., Paludo, J., McWilliams, R. R., Zhang, H., Li, Y., Kumar, A. B., Failing, J. J., Kottschade, L. A., Block, M. S., Markovic, S. N., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000669 · Cited by 51
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
Lamberti, G., Brighi, N., Maggio, I., Manuzzi, L., Peterle, C., Ambrosini, V., Ricci, C., Casadei, R., & Campana, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030747 · Cited by 51
Tumor-Infiltrating Lymphocyte Therapy and Neoantigens
Robbins, P. F. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000267 · Cited by 50
Kieny, A., Cribier, B. J., Meyer, N., Velten, M., Jegu, J., & Lipsker, D. M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31860 · Cited by 49
Samimi, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00427-9 · Cited by 50
Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review
Borella, F., Preti, M., Bertero, L., Collemi, G., Castellano, I., Cassoni, P., Cosma, S. D., Carosso, A. R., Bevilacqua, F., Gallio, N., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010190 · Cited by 49
Li, H., Chen, J., Li, Z., Chen, M., Ou, Z., Mo, M., Wang, R., Tong, S., Liu, P., Cai, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300110 · Cited by 49
"Present and future of immunotherapy in Neuroendocrine Tumors"
Albertelli, M., Dotto, A., Nista, F., Veresani, A., Patti, L., Gay, S., Sciallero, S., Boschetti, M., & Ferone, D. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09647-z · Cited by 51
Spassova, I., Ugurel, S., Kubat, L., Zimmer, L., Terheyden, P. A. M., Mohr, A., Bjorn-Andtback, H., Villabona, L. E. E., Leiter, U., Eigentler, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003198 · Cited by 48
Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes
Shalhout, S. Z., Kaufman, H. L., Emerick, K. S., & Miller, D. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2971 · Cited by 48
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Metastatic Merkel cell carcinoma response to nivolumab
Walocko, F. M., Scheier, B. Y., Harms, P. W., Fecher, L. A., & Lao, C. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0186-1 · Cited by 47
Response of Advanced Stage Recurrent Lymphoepithelioma-Like Carcinoma to Nivolumab
Kumar, V., Dave, V., Harris, J., & Huang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2017-0067 · Cited by 47
Virus-Specific T Cells: Broadening Applicability
Barrett, A. J., Prockop, S. E., & Bollard, C. M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.004 · Cited by 47
Wright, G. P., & Holtzman, M. P. (2017) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2017.10.045 · Cited by 47
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Gaiser, M. R., Bongiorno, M. A., & Brownell, I. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445966 · Cited by 49
Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer
Tanese, K., Nakamura, Y., Hirai, I., & Funakoshi, T. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00160 · Cited by 47
Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Zhuang, Y., Liu, C. X., Liu, J., & Li, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239398 · Cited by 47
Choi, F. D., Kraus, C. N., Elsensohn, A. N., Carley, S. K., Lehmer, L. M., Nguyen, R., Linden, K. G., & Shiu, J. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.077 · Cited by 46
Lamarca, Á., Walter, T., Pavel, M., Borbath, I., Freis, P., Nuñez, B., Childs, A., McNamara, M. G., Hubner, R. A., García‐Carbonero, R., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw277 · Cited by 46
Immunoprofiling as a predictor of patient’s response to cancer therapy—promises and challenges
Bethmann, D., Feng, Z., & Fox, B. A. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.005 · Cited by 48
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
Karpathiou, G., Chauleur, C., Mobarki, M., & Péoc’h, M. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152782 · Cited by 47
van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C. E., Ascierto, P. A., Asero, S. V. M. A., Blank, C. U., Block, M. S., Boland, G. M., Caracò, C., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11236-y · Cited by 47
Self-citationCurrent Clinical Trial Landscape of OX40 Agonists
Yadav, R., & Redmond, W. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01265-5 · Cited by 45
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 45
Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors
BUSAM, K. J., Pulitzer, M. P., Coit, D. C., Arcila, M. E., Leng, D., Jungbluth, A. A., & Wiesner, T. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.8 · Cited by 45
Wang, M., Ma, X., Guo, L., & Xia, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s146286 · Cited by 45
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Fischer, S., Ali, O. H., Jochum, W., Kluckert, T., Flatz, L., & Siano, M. (2018) · Oncology Research and Treatment · doi:10.1159/000487084 · Cited by 45
Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients
van Veenendaal, L. M., van Akkooi, A. C. J., Verhoef, C., Grünhagen, D. J., Klop, W. M. C., Valk, G. D., & Tesselaar, M. E. T. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25090 · Cited by 45
Akaike, T., Qazi, J. J., Anderson, A., Behnia, F., Shinohara, M. M., Akaike, G., Hippe, D. S., Thomas, H. M. T., Takagishi, S. R., Lachance, K., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19150 · Cited by 45
Self-citationZhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Glutsch, V., Kneitz, H., Gesierich, A., Goebeler, M., Haferkamp, S., Becker, J. C., Ugurel, S., & Schilling, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02832-0 · Cited by 46
TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer
Cui, L., Wang, X., & Zhang, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611444 · Cited by 45
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
Liu, Q., Qi, Y., Zhai, J., Kong, X., Wang, X., Wang, Z., Fang, Y., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.599207 · Cited by 45
The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
Mazziotta, C., Lanzillotti, C., Gafà, R., Touzé, A., Durand, M.-A., Martini, F., & Rotondo, J. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832047 · Cited by 44
Update on Merkel Cell Carcinoma
Tetzlaff, M. T., & Nagarajan, P. (2018) · Head and Neck Pathology · doi:10.1007/s12105-018-0898-2 · Cited by 44
A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis
Fallon, E. A., Girard, B., Chung, C., Lomas‐Neira, J., Heffernan, D. S., Monaghan, S. F., & Ayala, A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0917-377r · Cited by 45
Xu, M. J., Wu, S. Y., DAUD, A. I., Yu, S. S., & Yom, S. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0352-8 · Cited by 44
Self-citationNew developments in the biology and the treatment of metastatic Merkel cell carcinoma
Terheyden, P. A. M., & Becker, J. C. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000363 · Cited by 45
Updates on Merkel Cell Carcinoma
Emge, D. A., & Cardones, A. R. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.06.002 · Cited by 45
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000321 · Cited by 43
Clinical Significance of PD1 and PDL1 in Human Breast Cancer
Uhercik, M., Sanders, A. J., Owen, S., Davies, E. L., Sharma, A. K., Jiang, W. G., & Mokbel, K. (2017) · Anticancer Research · doi:10.21873/anticanres.11817 · Cited by 46
PD-1 blockade with nivolumab in endemic Kaposi sarcoma
Delyon, J., Bizot, A., Battistella, M., Madelaine, I., Vercellino, L., & Lebbé, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy006 · Cited by 43
Davis, D. A., Shrestha, P., Aisabor, A. I., Stream, A., Galli, V., Pise-Masison, C. A., Tagawa, T., Ziegelbauer, J. M., Franchini, G., & Yarchoan, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546544 · Cited by 44
Recent advances in HIV-associated Kaposi sarcoma
Pria, A. D., Pinato, D. J., Bracchi, M., & Bower, M. (2019) · F1000Research · doi:10.12688/f1000research.17401.1 · Cited by 43
Rico, G. T., Chan, M. M. K., & Loo, K. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102011 · Cited by 43
CDK5 Inhibition Abrogates TNBC Stem‐Cell Property and Enhances Anti‐PD‐1 Therapy
Bei, Y., Cheng, N., Chen, T., Shu, Y., Yang, Y., Yang, N., Zhou, X., Liu, B., Wei, J., Liu, Q., et al. (2020) · Advanced Science · doi:10.1002/advs.202001417 · Cited by 43
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Becker, J. C., Stang, A., Schrama, D., & Ugurel, S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00858-z · Cited by 42
Radiation and Immune Checkpoint Blockade: From Bench to Clinic
Shabason, J. E., & Minn, A. J. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.03.002 · Cited by 44
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 42
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 42
Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma
Haug, V., Behle, V., Benoit, S., Kneitz, H., Schilling, B., Goebeler, M., & Gesierich, A. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16780 · Cited by 42
Miller, N. J., Church, C. D., Fling, S. P., Kulikauskas, R. M., Ramchurren, N., Shinohara, M. M., Kluger, H. M., Bhatia, S., Lundgren, L. M., Cheever, M. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0450-7 · Cited by 42
Self-citationSun, L., Chin, R.-I., Gastman, B., Thorstad, W. L., Yom, S. S., Reddy, C. A., Nussenbaum, B. A., Wang, S. J., Knackstedt, T., Vidimos, A. T., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.5453 · Cited by 42
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018
Becker, J. C., Eigentler, T., Frerich, B., Gambichler, T., Grabbe, S., Höller, U., Klumpp, B. D., Loquai, C., Krause‐Bergmann, A., Müller-Richter, U. D. A., et al. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13841 · Cited by 42
Immunotherapies in rare cancers
Vivekanandhan, S., Bahr, D. A., Kothari, A., Ashary, M. A., Baksh, M., & Gabriel, E. M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01720-2 · Cited by 43
Cancer Immunotherapies: Are They as Effective in the Elderly?
Poropatich, K., Fontanarosa, J., Samant, S., Sosman, J. A., & Zhang, B. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0479-1 · Cited by 42
Kim, C., Rajan, A., DeBrito, P., & Giaccone, G. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.11.06 · Cited by 41
Varn, F. S., Schaafsma, E., Wang, Y., & Cheng, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1342 · Cited by 41
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
Blessin, N. C., Spriestersbach, P., Li, W., Mandelkow, T., Dum, D., Simon, R., Hube‐Magg, C., Lutz, F., Viehweger, F., Lennartz, M., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00496-7 · Cited by 41
How We Treat Merkel Cell Carcinoma: Within and Beyond Current Guidelines
Park, S. Y., Doolittle‐Amieva, C., Moshiri, Y., Akaike, T., Parvathaneni, U., Bhatia, S., Zaba, L. C., & Nghiem, P. (2021) · Future Oncology · doi:10.2217/fon-2020-1036 · Cited by 41
Self-citationImpact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 43
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
Jalili‐Nik, M., Soltani, A., Mashkani, B., Rafatpanah, H., & Hashemy, S. I. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107870 · Cited by 41
Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease
Siqueira, S. M., Campos‐do‐Carmo, G., dos Santos, A. L. S., Martins, C. L. C. D. S., & de Melo, A. C. (2023) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2022.09.003 · Cited by 40
Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention
Haley, C. T., Mui, U. N., Vangipuram, R., Rady, P. L., & Tyring, S. K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.09.062 · Cited by 40
Aung, P. P., Parra, E. R., Barua, S., Sui, D., Ning, J., Mino, B., Ledesma, D. A., Curry, J. L., Nagarajan, P., Torres-Cabala, C. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2355 · Cited by 40
Greene, E., Finak, G., D’Amico, L., Bhardwaj, N., Church, C. D., Morishima, C., Ramchurren, N., Taube, J. M., Nghiem, P., Cheever, M. A., et al. (2021) · Patterns · doi:10.1016/j.patter.2021.100372 · Cited by 40
Self-citationFructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity
Wang, B., Zhou, Y., Zhang, J., Jin, X., Wu, H., & Huang, H. (2019) · Theranostics · doi:10.7150/thno.38137 · Cited by 39
Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities
Sol, S., Boncimino, F., Todorova, K. A., Waszyn, S., & Mandinova, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137056 · Cited by 40
Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review
Tao, W., Sun, Q., Xu, B., & Wang, R. (2025) · Life · doi:10.3390/life15020283 · Cited by 39
Wang, L., Harms, P. W., Palanisamy, N., Carskadon, S. L., Cao, X., Siddiqui, J., Patel, R. M., Zelenka-Wang, S., Durham, A. B., Fullen, D. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0299 · Cited by 39
Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide
Paulson, K. G., & Bhatia, S. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7049 · Cited by 39
Self-citationBrar, G., & Shah, M. A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819869767 · Cited by 39
Improved survival in women versus men with merkel cell carcinoma
Tam, M. M., Luu, M., Barker, C. A., Gharavi, N. M., Hamid, O., Shiao, S. L., Nguyen, A. T., Lu, D. J., Ho, A. S., & Zumsteg, Z. S. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.034 · Cited by 39
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
Stachyra, K., Dudzisz‐Śledź, M., Bylina, E., Szumera‐Ciećkiewicz, A., Spalek, M. J., Bartnik, E., Rutkowski, P. L., & Czarnecka, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126305 · Cited by 40
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
McCaughan, G. J. B., FULHAM, M. J., Mahar, A. M., Soper, J., Hong, A., Stalley, P., Tattersall, M. H. N., & Bhadri, V. A. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0278-x · Cited by 38
PD ‐1 and PD‐L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma
Mitteldorf, C., Berisha, A., Tronnier, M., Pfaltz, M. C., & Kempf, W. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12973 · Cited by 38
Cabozantinib in Patients with Advanced Merkel Cell Carcinoma
Rabinowits, G., Lezcano, C. M., Catalano, P. J., McHugh, P., Becker, H., Reilly, M. M., Huang, J., Tyagi, A., Thakuria, M., Bresler, S. C., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0552 · Cited by 38
PD-1 Tumor Suppressor Signaling in T Cell Lymphomas
Wartewig, T., & Ruland, J. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.005 · Cited by 38
Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know
Akaike, G., Akaike, T., Fadl, S., Lachance, K., Nghiem, P., & Behnia, F. (2019) · Radiographics · doi:10.1148/rg.2019190102 · Cited by 38
Self-citationLi, T., Zhao, L., Yang, Y., Wang, Y., Zhang, Y., Guo, J., Chen, G., Qin, P., Xu, B., Ma, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2300 · Cited by 38
Jing, L., Ott, M., Church, C. D., Kulikauskas, R. M., Ibrani, D., Iyer, J. G., Afanasiev, O. K., Colunga, A., Cook, M. M., Xie, H. J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0647 · Cited by 38
Self-citationMechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
Blackmon, J. T., Dhawan, R., Viator, T. M., Terry, N. L. J., & Conry, R. M. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.02.003 · Cited by 37
Case Report: Pembrolizumab-Induced Type 1 Diabetes in a Patient with Metastatic Cholangiocarcinoma
Smith-Cohn, M., Gill, D. M., Voorhies, B. N., Agarwal, N., & Garrido‐Laguna, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0042 · Cited by 37
Bradford, D., Demko, S., Jin, S., Mishra-Kalyani, P. S., Beckles, A. R., Goldberg, K. B., Lemery, S. J., Ward, A., Keegan, P., & Pazdur, R. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0184 · Cited by 37
Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Pellat, A., & Coriat, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061677 · Cited by 37
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck
Karunaratne, Y. G., Gunaratne, D. A., & Veness, M. (2018) · Head & Neck · doi:10.1002/hed.25345 · Cited by 37
Checkpoint inhibition in pediatric hematologic malignancies
Davis, K. L., Agarwal, A. M., & Verma, A. R. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1383542 · Cited by 36
Tang, G., & Yin, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00154 · Cited by 36
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence
Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A. L., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734354 · Cited by 36
Chan, D. L. H., Rodríguez-Freixinós, V., Doherty, M. K., Wasson, K., Iscoe, N. A., Raskin, W., Hallet, J. I., Myrehaug, S. D., Law, C. H. L., Thawer, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.029 · Cited by 37
Ferrándiz‐Pulido, C., Leiter, U., Harwood, C. A., Proby, C. M., Guthoff, M., Scheel, C., Westhoff, T. H., Bavinck, J. N. B., Meyer, T., Nägeli, M., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004459 · Cited by 36
Recent Insights and Advances in the Management of Merkel Cell Carcinoma
Banks, P. D., Sandhu, S. K., Gyorki, D. E., Johnston, M. L., & Rischin, D. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.013367 · Cited by 35
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
Lamarca, Á., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., McNamara, M. G., Moghadam, S., Rogan, J., Mansoor, W., Hubner, R. A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24464 · Cited by 35
Metadata
- Authors
- Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
- Affiliations
- Johns Hopkins University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mount Sinai Hospital (US)
- ORCID
- Nghiem, Paul T.
- Bhatia, Shailender
- Lipson, Evan J.
- Kudchadkar, Ragini R.
- Miller, Natalie J.
- Berry, Sneha
- Chartash, Elliot K.
- Daud, Adil
- Fling, Steven P.
- Friedlander, Philip A.
- Kluger, Harriet M.
- Lundgren, Lisa
- Margolin, Kim
- Pardoll, Drew M.
- Reddy, Sunil A.
- Sharfman, William H.
- Sharon, Elad
- Shinohara, Michi M.
- Sunshine, Joel C.
- Taube, Janis M.
- Thompson, John A.
- Topalian, Suzanne L.
- Cheever, Martin A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-30
- Volume
- 374
- Issue
- 26
- Pages
- 2542-2552
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4927341
- OpenAlex
- W2339890238
- Cited by
- 1,258
- References
- 42
- Citations by year
- 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
- FWCI
- 103.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5u01ca154967-06)
- National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
- National Institute of General Medical Sciences (T32GM007266)
- Topics
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
